Ocugen to Present at 2024 BIO CEO & Investor Conference
February 21 2024 - 4:05PM
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines, today
announced that Dr. Shankar Musunuri, Chairman, Chief Executive
Officer and Co-Founder of Ocugen will present at the BIO CEO &
Investor Conference being held February 26-27, 2024, at the
Marriott Marquis in New York City.
Members of Ocugen’s leadership team will conduct
one-on-one meetings with registered investors and pharmaceutical
companies, showcasing the Company’s business and clinical
development strategy, recent corporate achievements, and
anticipated milestones.
Details of the presentation are as follows:Event:
BIO CEO & Investor Conference Date: Monday, February 26,
2024Presentation Time: 1:45 p.m. ETLocation: The Plymouth Room,
Marriott Marquis, New York
CityRegistration: https://bcic.bio.org/registration
Conference attendees that would like to schedule a
meeting with the Ocugen leadership team are encouraged to register
through the BIO CEO attendee portal.
About Ocugen, Inc. Ocugen,
Inc. is a biotechnology company focused on discovering, developing,
and commercializing novel gene and cell therapies, biologics, and
vaccines that improve health and offer hope for patients across the
globe. We are making an impact on patients’ lives through
courageous innovation—forging new scientific paths that harness our
unique intellectual and human capital. Our breakthrough modifier
gene therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us on Twitter and LinkedIn.
Forward-Looking
Statements This press release contains
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995, which are subject to
risks and uncertainties. We may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “proposed,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should,” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Such statements are subject to numerous
important factors, risks, and uncertainties that may cause actual
events or results to differ materially from our current
expectations. These and other risks and uncertainties are more
fully described in our periodic filings with the Securities and
Exchange Commission (SEC), including the risk factors described in
the section entitled “Risk Factors” in the quarterly and annual
reports that we file with the SEC. Any forward-looking statements
that we make in this press release speak only as of the date of
this press release. Except as required by law, we assume no
obligation to update forward-looking statements contained in this
press release whether as a result of new information, future
events, or otherwise, after the date of this press
release.
Contact: Tiffany Hamilton Head of
Communications Tiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024